✉news HealthMedicine first seen 4 h ago, last 47 min ago, peak #6
Insilico Medicine picks AI-designed obesity drug candidate ISM1354
Original: Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Hong Kong-based biotech Insilico Medicine has nominated ISM1354, a GIPR antagonist designed with its generative AI platform, as a preclinical development candidate for obesity and related metabolic disorders. It is the latest example of artificial intelligence compressing early drug discovery, and observers see it as a test of whether AI-designed molecules can advance into serious clinical pipelines for weight-loss treatment.
Why now: AI-discovered drugs targeting the hot obesity market are attracting wide attention from biotech investors and researchers.
Rank over time, top of the chart is #1. 4 snapshots from 4 h ago to 47 min ago.
Evidence
- Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity · Drug Target Review
API: https://socialmediatrends-api.osmike.com/v1/trends/751507